FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gary Tollefson

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Activities & Behaviors

Schizophrenic Psychology

Devices

Placebos

Co-author Network

Publications

TOP 3
Sanjay Dubé; Gary D Tollefson; Michael E Thase; Susan D Briggs; Luann E Van Campen; Michael Case; Mauricio Tohen
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Andrew A Nierenberg; John H Greist; Craig H Mallinckrodt; Apurva Prakash; Angelo Sambunaris; Gary D Tollefson; Madelaine M Wohlreich
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Stephanie L Rock; Sandra Woolson; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gary Tollefson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Sanjay Dubé; Gary D Tollefson; Michael E Thase; Susan D Briggs; Luann E Van Campen; Michael Case; Mauricio Tohen
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Bipolar disorders 2007;9(6):618-27.
2007: Andrew A Nierenberg; John H Greist; Craig H Mallinckrodt; Apurva Prakash; Angelo Sambunaris; Gary D Tollefson; Madelaine M Wohlreich
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Current medical research and opinion 2007;23(2):401-16.
2006: Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Stephanie L Rock; Sandra Woolson; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Biological psychiatry 2006;59(2):97-105.
2006: Sara A Corya; Doug Williamson; Todd M Sanger; Susan D Briggs; Michael Case; Gary D Tollefson
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Depression and anxiety 2006;23(6):364-72.
2005: Robert B Zipursky; Hongbin Gu; Alan I Green; Diana O Perkins; Mauricio Tohen; Joseph P McEvoy; Stephen M Strakowski; Tonmoy Sharma; René S Kahn; Raquel E Gur; Gary D Tollefson; Jeffrey A Lieberman
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
The British journal of psychiatry : the journal of mental science 2005;187():537-43.
2005: Haya Ascher-Svanum; Michael D Stensland; Bruce J Kinon; Gary D Tollefson
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Journal of psychopharmacology (Oxford, England) 2005;19(6 Suppl):110-7.
2005: Richard C Shelton; Douglas J Williamson; Sara A Corya; Todd M Sanger; Luann E Van Campen; Michael Case; Susan D Briggs; Gary D Tollefson
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
The Journal of clinical psychiatry 2005;66(10):1289-97.
2005: Stephen K Brannan; Craig H Mallinckrodt; Michael Detke; John G Watkin; Gary D Tollefson
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Journal of psychiatric research 2005;39(2):161-72.
2004: Anthony J Rothschild; Douglas J Williamson; Mauricio Tohen; Alan F Schatzberg; Scott W Andersen; Luann E Van Campen; Todd M Sanger; Gary D Tollefson
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Journal of clinical psychopharmacology 2004;24(4):365-73.
2004: Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Richard R J Lewine; Deborah A Yurgelun-Todd; Ruben C Gur; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
The American journal of psychiatry 2004;161(6):985-95.
2004: Martin Dossenbach; Vera Folnegovic-Smalc; Ljubomir Hotujac; Borben Uglesic; Gary D Tollefson; Starr L Grundy; Philip Friedel; Miroslav Miro Jakovljevic
Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry 2004;28(2):311-8.
2003: Charles Beasley; Virginia K Sutton; Susan H Hamilton; Daniel J Walker; Martin Dossenbach; Cindy C Taylor; Karla Alaka; Deborah Bykowski; Gary D Tollefson
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
Journal of clinical psychopharmacology 2003;23(6):582-94.
2003: John S Kennedy; D Jeste; Christopher J Kaiser; S Golshan; Gerald A Maguire; Gary D Tollefson; Todd M Sanger; Frank P Bymaster; Bruce J Kinon; Martin Dossenbach; Julie A Gilmore; Alan Breier
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
International journal of geriatric psychiatry 2003;18(11):1013-20.
2003: Mauricio Tohen; Eduard Vieta; Joseph Calabrese; Terence A Ketter; Gary Sachs; Charles L Bowden; Philip B Mitchell; Franca Centorrino; Richard Risser; Robert W Baker; Angela R Evans; Karin Beymer; Sanjay Dube; Gary D Tollefson; Alan Breier
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Archives of general psychiatry 2003;60(11):1079-88.
2003: Peter Feldman; Christopher J Kaiser; John S Kennedy; Virginia K Sutton; Pierre V Tran; Gary D Tollefson; Fan Zhang; Alan Breier
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
The Journal of clinical psychiatry 2003;64(9):998-1004.
2003: Craig H Mallinckrodt; Todd M Sanger; Sanjay Dubé; David J DeBrota; Geert Molenberghs; Raymond J Carroll; William Z Potter; Gary D Tollefson
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.
Biological psychiatry 2003;53(8):754-60.
2003: Robert W Baker; Mauricio Tohen; Jan Fawcett; Richard Risser; Leslie M Schuh; Eileen Brown; Virginia L Stauffer; Lixin Shao; Gary D Tollefson
Acute dysphoric mania: treatment response to olanzapine versus placebo.
Journal of clinical psychopharmacology 2003;23(2):132-7.
2002: Mauricio Tohen; K N Roy Chengappa; Trisha Suppes; Carlos A Zarate; Joseph Calabrese; Charles L Bowden; Gary S Sachs; David J Kupfer; Robert W Baker; Richard Risser; Elisabeth L Keeter; Peter Feldman; Gary D Tollefson; Alan Breier
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Archives of general psychiatry 2002;59(1):62-9.
2001: Douglas E Faries; John H Heiligenstein; Gary D Tollefson; William Z Potter
The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.
Journal of clinical psychopharmacology 2001;21(6):561-8.
2001: John S Kennedy; A Zagar; Frank P Bymaster; George Nomikos; Paula T Trzepacz; Julie A Gilmore; Matthew D Rotelli; Alan Breier; Gary D Tollefson
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International journal of geriatric psychiatry 2001;16 Suppl 1():S24-32.
2001: Mauricio Tohen; Fan Zhang; Cindy C Taylor; P Burns; Carlos A Zarate; Todd M Sanger; Gary D Tollefson
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder.
Journal of affective disorders 2001;65(1):85-93.
2001: BR Basson; Bruce J Kinon; Cindy C Taylor; K A Szymanski; Julie A Gilmore; Gary D Tollefson
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
The Journal of clinical psychiatry 2001;62(4):231-8.
2001: Bruce J Kinon; BR Basson; Julie A Gilmore; Gary D Tollefson
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
The Journal of clinical psychiatry 2001;62(2):92-100.
2001: Regina C Casper; Gary D Tollefson; M E Nilsson
No gender differences in placebo responses of patients with major depressive disorder.
Biological psychiatry 2001;49(2):158-60.
2001: Martin Dossenbach; P Kratky; Michael Schneidman; S L Grundy; Stephen Metcalfe; Gary D Tollefson; R H Belmaker
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
The Journal of clinical psychiatry 2001;62 Suppl 2():28-34.
2001: Gary D Tollefson; Martin Birkett; Geri Kiesler; A J Wood
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
Biological psychiatry 2001;49(1):52-63.
2001: Richard C Shelton; Gary D Tollefson; Mauricio Tohen; S Stahl; K S Gannon; Thomas G Jacobs; W R Buras; Frank P Bymaster; W Zhang; K A Spencer; Peter Feldman; Herbert Y Meltzer
A novel augmentation strategy for treating resistant major depression.
The American journal of psychiatry 2001;158(1):131-4.
2000: JS Street; WS Clark; K S Gannon; Jeffrey L Cummings; Frank P Bymaster; Roy Tamura; S J Mitan; Deborah L Kadam; Todd M Sanger; Peter Feldman; Gary D Tollefson; Alan Breier
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Archives of general psychiatry 2000;57(10):968-76.
2000: J N Beuzen; M Avnon; R H Belmaker; A Elizur; M Mark; Hanan Munitz; Michael Schneidman; D Shoshani; P Kratky; S L Grundy; Gary D Tollefson
The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
Clinical therapeutics 2000;22(9):1021-34.
2000: Mauricio Tohen; Thomas G Jacobs; SL Grundy; S L McElroy; M C Banov; P G Janicak; Todd M Sanger; Richard Risser; Fan Zhang; V Toma; J Francis; Gary D Tollefson; Alan Breier
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Archives of general psychiatry 2000;57(9):841-9.
2000: Wei Zhang; Kenneth W Perry; David T Wong; B D Potts; J Bao; Gary D Tollefson; Frank P Bymaster
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(3):250-62.
2000: P Bech; P Cialdella; Margaret Haugh; Martin Birkett; A Hours; J P Boissel; Gary D Tollefson
Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression.
The British journal of psychiatry : the journal of mental science 2000;176():421-8.
2000: Michael Poyurovsky; Pnina Dorfman-Etrog; Haggai Hermesh; Hanan Munitz; Gary D Tollefson; Abraham Weizman
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
International clinical psychopharmacology 2000;15(3):169-73.
2000: Scot E Purdon; B D Jones; Emmanuel Stip; Alain Labelle; Donald Addington; Stacy R David; Alan Breier; Gary D Tollefson
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Archives of general psychiatry 2000;57(3):249-58.
1999: Gary D Tollefson; MA Dellva; C A Mattler; John M Kane; D A Wirshing; Bruce J Kinon
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
Journal of clinical psychopharmacology 1999;19(5):435-43.
1999: Gary D Tollefson; Scott W Andersen; Pierre V Tran
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Biological psychiatry 1999;46(3):365-73.
1999: Susan H Hamilton; Dennis A Revicki; Eric T Edgell; LA Genduso; Gary D Tollefson
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
PharmacoEconomics 1999;15(5):469-80.
1999: Mauricio Tohen; Todd M Sanger; S L McElroy; Gary D Tollefson; K N Roy Chengappa; D G Daniel; F Petty; F Centorrino; R Wang; SL Grundy; M G Greaney; Thomas G Jacobs; Stacy R David; V Toma
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
The American journal of psychiatry 1999;156(5):702-9.
1999: David Michelson; M Pollack; R Bruce Lydiard; Roy Tamura; RG Tepner; Gary D Tollefson
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group.
The British journal of psychiatry : the journal of mental science 1999;174():213-8.
1999: Gary D Tollefson; Todd M Sanger
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Schizophrenia research 1999;35 Suppl():S13-21.
1999: Charles Beasley; MA Dellva; Roy Tamura; H Morgenstern; WM Glazer; K Ferguson; Gary D Tollefson
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
The British journal of psychiatry : the journal of mental science 1999;174():23-30.
1999: Pierre V Tran; Gary D Tollefson; Todd M Sanger; Y Lu; Paul H Berg; Charles Beasley
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
The British journal of psychiatry : the journal of mental science 1999;174():15-22.
1999: Gary D Tollefson; A J Kuntz
Review of recent clinical studies with olanzapine.
The British journal of psychiatry. Supplement 1999;(37):30-5.
1999: Gary D Tollefson; Scott W Andersen
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
The Journal of clinical psychiatry 1999;60 Suppl 5():23-9; discussion 30.
1999: Todd M Sanger; J A Lieberman; Mauricio Tohen; SL Grundy; C Beasley; Gary D Tollefson
Olanzapine versus haloperidol treatment in first-episode psychosis.
The American journal of psychiatry 1999;156(1):79-87.
1998: David Michelson; R Bruce Lydiard; M H Pollack; Roy Tamura; S L Hoog; RG Tepner; MA Demitrack; Gary D Tollefson
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.
The American journal of psychiatry 1998;155(11):1570-7.
1998: Pierre V Tran; MA Dellva; Gary D Tollefson; A L Wentley; Charles Beasley
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
The British journal of psychiatry : the journal of mental science 1998;172():499-505.
1998: Gary D Tollefson; Todd M Sanger; Charles Beasley; Pierre V Tran
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Biological psychiatry 1998;43(11):803-10.
1998: Gary D Tollefson; Todd M Sanger; Y Lu; M E Thieme
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Archives of general psychiatry 1998;55(3):250-8.
1998: TR Hylan; DP Buesching; Gary D Tollefson
Health economic evaluations of antidepressants: a review.
Depression and anxiety 1998;7(2):53-64.
1997: MA Dellva; P Tran; Gary D Tollefson; A L Wentley; Charles Beasley
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Psychiatric services (Washington, D.C.) 1997;48(12):1571-7.
1997: Pierre V Tran; Susan H Hamilton; A J Kuntz; JH Potvin; Scott W Andersen; C Beasley; Gary D Tollefson
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Journal of clinical psychopharmacology 1997;17(5):407-18.
1997: Gary D Tollefson; Charles Beasley; Roy Tamura; Pierre V Tran; JH Potvin
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
The American journal of psychiatry 1997;154(9):1248-54.
1997: AM Crawford; Charles Beasley; Gary D Tollefson
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Schizophrenia research 1997;26(1):41-54.
1997: Pierre V Tran; MA Dellva; Gary D Tollefson; Charles Beasley; JH Potvin; Geri Kiesler
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
The Journal of clinical psychiatry 1997;58(5):205-11.
1997: Charles Beasley; Susan H Hamilton; AM Crawford; MA Dellva; Gary D Tollefson; Pierre V Tran; O Blin; J N Beuzen
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1997;7(2):125-37.
1997: Neil Bodick; Walter W Offen; Allan Levey; Neal R Cutler; S Gauthier; Andrew Satlin; Harlan E Shannon; Gary D Tollefson; Kurt Rasmussen; Frank P Bymaster; D J Hurley; W Z Potter; S M Paul
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Archives of neurology 1997;54(4):465-73.
1997: Gary D Tollefson; Todd M Sanger
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
The American journal of psychiatry 1997;154(4):466-74.
1997: Gary D Tollefson; Charles Beasley; Pierre V Tran; JS Street; J A Krueger; Roy Tamura; K A Graffeo; M E Thieme
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
The American journal of psychiatry 1997;154(4):457-65.
1997: J F Wernicke; M E Sayler; S C Koke; D K Pearson; Gary D Tollefson
Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Depression and anxiety 1997;6(1):31-9.
1997: Charles Beasley; Gary D Tollefson; Pierre V Tran
Safety of olanzapine.
The Journal of clinical psychiatry 1997;58 Suppl 10():13-7.
1997: Charles Beasley; Gary D Tollefson; Pierre V Tran
Efficacy of olanzapine: an overview of pivotal clinical trials.
The Journal of clinical psychiatry 1997;58 Suppl 10():7-12.
1996: Gary D Tollefson; M E Sayler
Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
Depression and anxiety 1996;4(6):294-311.
1996: Gary D Tollefson
Cognitive function in schizophrenic patients.
The Journal of clinical psychiatry 1996;57 Suppl 11():31-9.
1996: Gary D Tollefson; J H Heiligenstein; S L Tollefson; M A Birkett; D L Knight; Charles Nemeroff
Is there a relationship between baseline and treatment-associated changes in [3H]-IMI platelet binding and clinical response in major depression?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(1):47-53.
1995: L M Koran; Susan H Hamilton; M Hertzman; B S Meyers; A E Halaris; Gary D Tollefson; J M Downs; D G Folks; D V Jeste; L W Lazarus
Predicting response to fluoxetine in geriatric patients with major depression.
Journal of clinical psychopharmacology 1995;15(6):421-7.
1995: J H Heiligenstein; John Ware; K M Beusterien; P J Roback; C Andrejasich; Gary D Tollefson
Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.
International psychogeriatrics / IPA 1995;7 Suppl():125-37.
1995: Gary D Tollefson; J C Bosomworth; J H Heiligenstein; J H Potvin; S Holman
A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group.
International psychogeriatrics / IPA 1995;7(1):89-104.
1994: Gary D Tollefson; J H Greist; J W Jefferson; J H Heiligenstein; M E Sayler; S L Tollefson; K Koback
Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine.
Journal of clinical psychopharmacology 1994;14(6):385-91.
1994: Gary D Tollefson; M Birkett; L Koran; LA Genduso
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
The Journal of clinical psychiatry 1994;55 Suppl():69-76; discussion 77-8.
1994: Gary D Tollefson; A H Rampey; J H Potvin; M A Jenike; A J Rush; R A kominguez; L M Koran; M K Shear; W Goodman; LA Genduso
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
Archives of general psychiatry 1994;51(7):559-67.
1994: Gary D Tollefson; A H Rampey; Charles Beasley; G G Enas; J H Potvin
Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
Journal of clinical psychopharmacology 1994;14(3):163-9.
1994: J H Heiligenstein; Gary D Tollefson; D E Faries
Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.
Journal of affective disorders 1994;30(3):163-73.
1994: Gary D Tollefson; S L Holman; M E Sayler; J H Potvin
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
The Journal of clinical psychiatry 1994;55(2):50-9.
1994: Gary D Tollefson; S L Holman
How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo.
International clinical psychopharmacology 1994;9(4):245-50.
1993: Gary D Tollefson; J Fawcett; G Winokur; Charles Beasley; J H Potvin; D E Faries; A H Rampey; M E Sayler
Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1993;5(4):209-24.
1993: Gary D Tollefson
Adverse drug reactions/interactions in maintenance therapy.
The Journal of clinical psychiatry 1993;54 Suppl():48-58; discussion 59-60.
1993: A Wood; Gary D Tollefson; M Birkett
Pharmacotherapy of obsessive compulsive disorder--experience with fluoxetine.
International clinical psychopharmacology 1993;8(4):301-6.
1993: Gary D Tollefson; E Souetre; L Thomander; J H Potvin
Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes.
International clinical psychopharmacology 1993;8(4):281-93.
1993: Gary D Tollefson; S L Holman
Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
International clinical psychopharmacology 1993;8(4):253-9.
1993: J H Heiligenstein; Gary D Tollefson; D E Faries
A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia.
International clinical psychopharmacology 1993;8(4):247-51.
1992: Gary D Tollefson; J Montague-Clouse; S L Tollefson
Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone).
Journal of clinical psychopharmacology 1992;12(1):19-26.
1991: Gary D Tollefson; M Luxenberg; R Valentine; G Dunsmore; S L Tollefson
An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder.
The Journal of clinical psychiatry 1991;52(12):502-8.
1991: Gary D Tollefson
Antidepressant treatment and side effect considerations.
The Journal of clinical psychiatry 1991;52 Suppl():4-13.
1991: Gary D Tollefson; S P Lancaster; J Montague-Clouse
The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency.
Psychopharmacology bulletin 1991;27(2):163-70.
1991: Gary D Tollefson; J Montague-Clouse; S P Lancaster
The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population.
The Journal of neuropsychiatry and clinical neurosciences 1991;3(3):314-9.
1989: Gary D Tollefson; J Montague-Clouse; T Lesan; M J Garvey
Pharmacokinetic properties of maprotiline in geriatric depression.
Journal of clinical psychopharmacology 1989;9(4):313-5.
1989: Gary D Tollefson; M Godes; J Montague-Clouse; S P Lancaster; M J Garvey
Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety.
Journal of clinical psychopharmacology 1989;9(2):132-6.
1989: Gary D Tollefson; M Godes; J B Warren; E Haus; M Luxenberg; M Garvey
Lymphopenia in primary degenerative dementia.
Journal of psychiatric research 1989;23(3-4):191-9.
1988: Gary D Tollefson; J Montague-Clouse
Alprazolam plus buspirone in treatment of anxiety.
The American journal of psychiatry 1988;145(3):379-80.
1986: Gary D Tollefson; J Zander; M Luxenberg; S Saxena; M Godes; Michael J Garvey
Prediction of postdexamethasone cortisol levels by serum sodium levels in patients with major depression.
The American journal of psychiatry 1986;143(1):81-4.